Primary Cardiac Angiosarcoma: A Case Report

Primer Kardiyak Anjiosarkoma: Bir Olgu Sunumu

Ayşe Gök Durnalı¹, Ayşe Yüksel², Muzaffer Bedir Altundağ³, Murat Vural¹, Berna Öksüzoğlu⁴, Necati Alkış⁵

¹Dr. A. Y. Ankara Onkoloji Eğitim ve Araştırma Hastanesi, Tibbi Onkoloji Kliniği, Ankara, Türkiye
²Ankara Onkoloji Eğitim ve Araştırma Hastanesi, Kardiyoloji Kliniği, Ankara, Türkiye
³Ankara Onkoloji Eğitim ve Araştırma Hastanesi, Radyasyon Onkolojisi Kliniği, Ankara, Türkiye
⁴Ankara Numune Eğitim ve Araştırma Hastanesi, Radyoloji Kliniği, Ankara, Türkiye

Abstract

Primary cardiac angiosarcoma is a rare disease with poor prognosis. A 34-year-old male patient who underwent an open cardiac surgery and diagnosed as cardiac angiosarcoma on the right atrium was admitted to the medical oncology department. Complete curative resection of the tumor was not possible and postoperatively 6 cycles of combination chemotherapy regimen (ifosphamide with mesna protection and doxorubicin) was given. Patient had stable disease for 8 months, and after progression a second-line chemotherapy (paclitaxel) was started but he died after 15 months of diagnosis. Since curative resections are not possible in most of the cardiac angiosarcoma cases, further treatment options are desperately needed.

Key words: cardiac angiosarcoma, chemotherapy

Introduction:

Most of the malignant neoplasms located in the heart are metastatic tumors. Primary cardiac tumors are quite rare, and only 25% of them are malignant (1, 2). One of the malignant primary neoplasm of the heart, namely cardiac angiosarcoma originates from the mesenchymal tissue and endothelial subepicardium. It occurs more frequently in young middle-aged patients and its prognosis is very poor (3, 4). We have reported a patient with this disease and our treatment outcomes.

Case Report:

A 34-year-old man was admitted to the medical oncology department with the diagnosis of cardiac angiosarcoma. In his past history, approximately one month ago, he was admitted to emergency department with chest pain, massive pleural effusion was detected on chest X-ray, and chest computed tomography (CT) showed a mass in the right atrium. The chest tube was inserted and he underwent an open cardiac surgery. On exploration, pericardium was sticky and enclosed by vascular structures, there was a mass with irregular borders on the right atrium extending to the right ventricle, and invasion to the right pleura. Since complete curative resection was not possible, partial resection was undertaken. Pathological examination of resected material was reported as well-differentiated angiosarcoma with vascular invasion, 4x3 cm in size, and there was 9 mitosis per 10 high power field (HPF) and...
eventually surgical margins were tumor-positive.

Cardiac magnetic resonance imaging (MRI), taken after admission to medical oncology department, revealed a mass, 81x55 mm in size, invading the anterior wall of right ventricle, protruding into the cavity of right ventricle with the suspicion of invasion to tricuspid valve and right atrium and aorta (Figure 1).

![Figure 1](image1)

**Figure 1:** Magnetic resonance imaging taken after cardiac surgery revealed a mass, 81x55 mm in size, invading the anterior wall of right ventricle.

Transthoracic echocardiography confirmed a semi mobile mass 50x40mm in size in the right atrium (Figure 2).

![Figure 2](image2)

**Figure 2:** Transthoracic echocardiography showed a semi mobile mass 50x40mm in size in the right atrium

Abdominal ultrasonography was normal. A combination chemotherapy regimen used for other soft tissue sarcomas (ifosphamide 1800mg/m2/day on 1-5 days, with mesna protection, doxorubicin 60mg/m2/day on day 1, every 3 weeks), was started, and after the 1st cycle, febrile neutropenia developed and chemotherapy doses were reduced by 20% at the following cycles. After 3 cycles of chemotherapy, there was a minimal regression on MRI findings and 3 more cycles were given. After 6 cycles, MRI and echocardiography revealed stable disease. Positron Emission Tomography (PET-CT) showed increased uptake of fluorodeoxyglucose only on right ventricular region. He was consulted to the heart surgery clinics for a second operation, however no more curative operation was considered to be possible. He was consulted with the radiotherapy clinics and radiotherapy was not indicated. About 5 months later, there was progression on cardiac MRI findings and chest CT showed metastatic nodules, 2 cm in diameter. With these findings second line chemotherapy (paclitaxel 175mg/m2/day on day 1, every 21 days) was started. After 3 cycles of paclitaxel chemotherapy, minimal regression was achieved, but after 6 cycles, clinical findings and imaging findings showed progression. Due to cardiac and respiratory failure, the patient died 45 days after the last chemotherapy cycle and 15 months after the initial diagnosis.

**Discussion:**

Primary cardiac angiosarcoma is seen infrequently, accounting for less than 10% of all primary cardiac tumors (5). It is seen mostly in right side of the heart and in young to middle-aged patients (3,4). Symptoms vary according to the size and site of the tumor: chest pain, cough, syncope, dyspnea, lung edema, arrhythmia, peripheral edema, dizziness are the most common symptoms (3,4,6,7,8). Transthoracic echocardiography and computed tomography (CT) are the useful tools for initial evaluation and suggestion of diagnosis, and MRI is helpful in preoperative differential diagnosis (8,9). Diagnosis of cardiac angiosarcoma is often confirmed by the resection of the tumor. Because of the fragility of the tumor, myocardial biopsy is not recommended. In the presented case, CT was used for the initial evaluation; and cardiac MRI and echocardiography for the evaluation of residual tumor and chemotherapy responses. Because of the rarity of this disease, there has been no standard treatment guideline (10,11). In some cases, radiotherapy after surgery was reported to improve outcomes.
(2,10). There are insufficient data about the role of adjuvant chemotherapy. Chemotherapy regimens containing doxorubicin, ifosfamide, cisplatin and paclitaxel have been tried (6,12,13, 14). For advanced disease doxorubicin and weekly paclitaxel seem to provide some improvement in progression free survival (14). Several phase II trials have been published investigating vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors such as sorafenib, imatinib, pazopanib, sunitinib and anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab, demonstrated that some angiosarcoma patients had response or durable disease stabilization on these agents (14, 15, 16). One of these phase II studies, sorafenib showed limited antitumor activity in pretreated patients only, for both visceral and superficial angiosarcoma, with short duration of tumor control (16). Further studies are needed to confirm these findings and to identify which patients will benefit from these agents.

Whatever the chosen treatment modality, the prognosis of cardiac angiosarcoma is poor and the median survival is between 3 to 12 months. Surgical excision of the tumor may be associated with better survival increasing up to 21 months (10). If surgical resection is not possible, median survival is approximately 6 months (7,17). In one case report of a metastatic patient, multimodality palliative treatment with neoadjuvant and adjuvant chemotherapy and surgery improved survival (18). The patient presented herein had minimal symptomatic disease for about 8 months with multimodality treatment including incomplete resection and chemotherapy.

In conclusion, primary cardiac angiosarcoma is a rare and aggressive tumor with poor prognosis. For treatment options; surgical resection should be considered first and chemotherapy and radiotherapy may be indicated for palliative purposes.

**Conflict of interest:** None

**References:**